The real reason Musk left DOGE?

In Today’s News

Trump Cuts Threaten Safety Training for Workers

Last summer, Robbie Roberge faced a terrifying moment as flames engulfed the galley of his fishing vessel, Three Girls. The boat, named after his daughters, was his livelihood and pride. Located in Newburyport, Massachusetts, Roberge’s ordeal underscores growing concerns about reduced safety training resources, particularly in high-risk jobs like commercial fishing. As funding faces cuts under new federal proposals, critics argue that slashing safety initiatives puts lives at risk. With incidents on the rise, this debate has drawn national attention, especially in coastal towns where such careers are prevalent. Read More >>

China Bristles at Macron’s Taiwan-Ukraine Comparison

China reacted strongly this weekend to French President Emmanuel Macron’s remarks linking defense of Ukraine to protection of Taiwan. During a speech in Singapore, Macron warned of broader global implications if authoritarian expansion goes unchecked. China called the comparison a “double standard,” stressing its view that Taiwan remains a domestic matter. These tensions come amid increased regional military activity and rising pressure on Asian nations to bolster defense alliances. Macron’s comments may further deepen divisions in diplomatic circles, especially in Southeast Asia. Read More >>

Pentagon Chief Sounds Alarm on China, Pushes for More Defense Spending

U.S. Defense Secretary Pete Hegseth addressed the Shangri-La Dialogue in Singapore, warning of an “imminent” threat from China. In urging regional allies to increase defense budgets, he highlighted growing concern over Beijing’s posture in the South China Sea and Taiwan Strait. Hegseth’s speech, his first at the annual summit, outlined the U.S. view that collective readiness is vital. As tensions escalate, nations like Japan and South Korea may soon announce fresh commitments. Hegseth’s remarks reflect broader American strategy toward maintaining stability in Asia. Read More >>

Gilead and Merck Team Up in Breast Cancer Trial Breakthrough

New data presented over the weekend shows that combining Gilead’s Trodelvy with Merck’s Keytruda can significantly reduce the progression of aggressive breast cancer. In a large clinical trial, the treatment cut the risk by 35%, offering hope for patients with limited options. Experts say this combo therapy may quickly become standard care if approved. These results could reshape oncology protocols, providing more targeted, effective approaches for early-stage diagnoses. Read More >>

Sponsored Picks

Disclaimer: This is a paid advertisement for educational purposes only and does not constitute financial advice. Investing involves risk and may not be suitable for all individuals. Past performance does not guarantee future results.
Trading Cheat Sheet is owned and operated by PROTRADING RESEARCH LLC. We are not licensed financial advisors. Always consult with a certified financial professional before making investment decisions.

IMPORTANT NOTICE AND DISCLAIMER
PROTRADING RESEARCH LLC (“PTR”), the owner of this website (the “Website”), cannot guarantee the accuracy or completeness of the information contained in any article, email, newsletter, or other publication posted on or viewed in connection with this website (the “Publications”). The author or authors of those Publications are solely responsible for their contents. PTR has not done any research or due diligence into the markets, industries, or companies which may appear or be mentioned in the Publications. PTR will NOT be liable for any loss or damage caused by a reader’s reliance on information posted on the Website or contained in the Publications.

FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE.
This Website and the Publications are for educational and informational purposes only. This Website and the Publications do not purport to be a complete analysis of any company’s financial position. This Website, the Publications or any statements made in the Publications are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. This Website or the statements made in the Publications should NOT be relied upon for purposes of transacting in any securities posted on the Website or mentioned in the Publications, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security posted on this Website or mentioned in any Publications.

SUBSTANTIAL RISK IN INVESTMENT.
Any individual who chooses to invest in any securities including those mentioned in the Publications should do so with caution. Investing or transacting in securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers bear responsibility for their own investment research and decisions and should review all investment decisions with a licensed or registered investment professional.

NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER
Neither PTR nor any of its respective owners or employees are registered or licensed as a securities broker-dealer, broker, an investment advisor, or an investment advisor representative with the U.S. Security Securities and Exchange Commission (SEC), any state securities regulatory authority, or any self-regulatory organization.

To view our full policies: Disclaimer | Privacy Policy | Terms & Conditions

Trading Cheat Sheet
203 N La Salle Street, Suite 2100 | Chicago, IL 60601

unsubscribe